Type 1 Diabetes Trial, Recruiting (NCT07260110)

Type 1 Diabetes Trial, Recruiting NCT07260110 Sponsor: Sanofi Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT07260110 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have a history of stage 2 type 1 diabetes, confirmed in their medical records, including the presence of one or more diabetes-related antibodies and abnormal blood sugar levels
People who, at the time of joining, have not yet been diagnosed with full type 1 diabetes (stage 3), or whose progression to stage 3 happened within the last 18 months
People who are 8 years of age or older at the time of joining the trial
People who are 8 years of age or older at the time of receiving the study drug infusion, if that infusion takes place
People who receive their medical care in the United States
People who are able to provide written consent to participate

Who may not be able to join:

People who do not complete the baseline survey at the start of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-633-1610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07260110

Sponsor: Sanofi

Phase: Not Applicable

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: 800-633-1610

More information: https://clinicaltrials.gov/study/NCT07260110

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have a history of stage 2 type 1 diabetes, confirmed in their medical records, including the presence of one or more diabetes-related antibodies and abnormal blood sugar levels
People who, at the time of joining, have not yet been diagnosed with full type 1 diabetes (stage 3), or whose progression to stage 3 happened within the last 18 months
People who are 8 years of age or older at the time of joining the trial
People who are 8 years of age or older at the time of receiving the study drug infusion, if that infusion takes place
People who receive their medical care in the United States
People who are able to provide written consent to participate

Who may not be able to join:

People who do not complete the baseline survey at the start of the trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Sanofi

Registry

ClinicalTrials.gov

Start date

31 October 2025

Est. completion

3 December 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in participant and caregiver-reported outcomes from survey responses: ease of diabetes management questions; Change in participant and caregiver-reported outcomes from survey responses: Psychological well-being World Health Organization-5 (WHO-5); Change in participant and caregiver-reported outcomes from survey responses: State-Trait Anxiety Inventory (STAI); Change in participant and caregiver-reported outcomes from survey responses: Type 1 Diabetes Distress Assessment System-Core Scale (T1-DDAS CORE); Change in participant and caregiver-reported outcomes from survey responses: Diabet...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov